Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer

BACKGROUND: Complete surgical resection of breast cancer is a powerful determinant of patient outcome, and failure to achieve negative margins results in reoperation in between 30% and 60% of patients. We hypothesize that repurposing Food and Drug Administration approved antibodies as tumor-targetin...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Surg Res
Asıl Yazarlar: Korb, Melissa L., Hartman, Yolanda E., Kovar, Joy, Zinn, Kurt R., Bland, Kirby I., Rosenthal, Eben L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4354808/
https://ncbi.nlm.nih.gov/pubmed/24360117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jss.2013.11.1089
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller